IO Immuno-Oncology, the new frontier in the treatment of cancer: Immune checkpoint blockade with monoclonal antibodies (mAbs).Posted by Michele | Disease Overview/Trends | No Comments
Immune checkpoint blockade
Targeting the immune system instead of the cancer cells, these new drugs are revolutionizing the treatment of cancer.
More specifically, proteins of the immune-checkpoint pathways on the surface of T cells play important roles in the development of immune tolerance. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) signaling for instance, inhibits T-cell activation. Thus CTLA-4 blockade using anti-CTLA-4 monoclonal antibody therapy has great potential because suppression of inhibitory signals results in the generation of an antitumor T-cell response. Other important immune-checkpoint proteins are Programmed cell Death protein 1 (PD-1), and Programmed Death-Ligand 1 (PD-L1), its ligand.